# LDLR (Low-Density Lipoprotein Receptor): Endocytosis, Familial Hypercholesterolemia, and [PCSK9](/knowledge/bioinformatics/genes/medical-genetics/pcsk9-gene-structure-function-pathway) Binding


## Key Takeaways

-   The Low-Density Lipoprotein Receptor (LDLR) is a transmembrane glycoprotein essential for clearing cholesterol-rich lipoproteins (LDL, VLDL remnants) from the plasma via clathrin-mediated endocytosis, thereby maintaining cholesterol homeostasis.
-   Mutations in the *LDLR* gene are the primary cause of Familial Hypercholesterolemia (FH), an autosomal dominant disorder leading to elevated LDL-C, tendon xanthomas, and premature atherosclerosis, with mutations classified into five functional classes (null, transport-defective, binding-defective, internalization-defective, recycling-defective).
-   Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) post-translationally regulates LDLR by binding to its extracellular domain, preventing receptor recycling and targeting it for lysosomal degradation, thus increasing plasma LDL-C levels.
-   LDLR serves as a critical entry receptor for various viruses, including Hepatitis C Virus (HCV), Crimean-Congo Hemorrhagic Fever Virus (CCHFV), and alphaviruses, highlighting its role in host-pathogen interactions beyond lipid metabolism.
-   Therapeutic strategies for hypercholesterolemia, such as statins and PCSK9 inhibitors, target the LDLR pathway by upregulating receptor expression or preventing its degradation, respectively, to enhance LDL-C clearance.

---

## Executive Summary & Key Metadata

The Low-Density Lipoprotein Receptor (LDLR) is a classical endocytic receptor that governs plasma cholesterol homeostasis through the clathrin-mediated uptake of cholesterol-rich lipoproteins. Since its discovery in the 1970s by Brown and Goldstein, LDLR has served as the archetype for receptor-mediated endocytosis and has been central to our understanding of familial hypercholesterolemia (FH), a common autosomal dominant disorder. The receptor binds apolipoprotein B-100 (ApoB-100) on LDL particles and apolipoprotein E (ApoE) on very-low-density lipoprotein (VLDL) remnants, internalizing them via coated pits. The gene product is also a critical nexus for the action of proprotein convertase subtilisin/kexin type 9 (PCSK9), which post-translationally regulates LDLR degradation. Beyond its canonical role in lipid metabolism, LDLR has been implicated in viral entry (e.g., hepatitis C virus, Crimean-Congo hemorrhagic fever virus, and alphaviruses), cancer biology, and inflammatory signaling. This manual provides a comprehensive, publication-grade reference covering the genomic architecture, structural biology, signaling pathways, pathogenic mutations, [pharmacogenomics](/knowledge/bioinformatics/pharmacogenomics-tailoring-drugs-to-genetic-profiles), and bioinformatic resources associated with LDLR.

| **Attribute** | **Value** |
| :--- | :--- |
| **HGNC Symbol** | LDLR |
| **UniProt Accession** | P01130 |
| **Representative PDB ID** | 1N7D |
| **Chromosomal Locus** | 19p13.2 |
| **Primary Molecular Function** | Receptor-mediated endocytosis of low-density lipoproteins; cholesterol homeostasis |
| **Disease & Pathology Associations** | Familial hypercholesterolemia (FH); premature atherosclerosis; coronary heart disease; viral susceptibility; cancer prognosis |

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The human *LDLR* gene is located on the short arm of chromosome 19 at band 19p13.2. This locus was first assigned to chromosome 19 through somatic cell hybrid studies, which demonstrated synteny between the receptor gene, the ligand (ApoE), and the disease phenotype of familial hypercholesterolemia [78]. The gene spans approximately 45 kilobases (kb) of genomic DNA and comprises 18 exons and 17 introns. The coding sequence is distributed across exons 2 through 18, with exon 1 encoding the 5' untranslated region (UTR) and the signal peptide.

The genomic organization of *LDLR* is highly conserved across mammals, reflecting its fundamental role in lipid metabolism. The exon-intron boundaries correlate remarkably well with the functional protein domains, a classic example of exon shuffling in evolution. Specifically, exons 2–6 encode the ligand-binding domain (composed of seven complement-type repeats), exon 7 encodes the epidermal growth factor (EGF) precursor homology domain, exons 9–14 encode the EGF-like repeats and the β-propeller domain, exon 15 encodes the O-linked sugar domain, exon 16 encodes the transmembrane domain, and exons 17–18 encode the cytoplasmic tail [8].

### 1.2 Promoter Architecture and Transcriptional Regulation

The promoter region of *LDLR* lacks a canonical TATA box but contains several critical cis-acting elements essential for basal and regulated transcription. The core promoter spans approximately 200 base pairs upstream of the transcription start site and includes:

- **Sterol Regulatory Element (SRE-1):** A 10-bp sequence (5'-ATCACCCCAC-3') located approximately 150 bp upstream of the transcription start site. This element is the binding site for the sterol regulatory element-binding proteins (SREBPs), primarily SREBP-2. Under conditions of low intracellular cholesterol, SREBP-2 is cleaved from the endoplasmic reticulum membrane and translocates to the nucleus, where it activates *LDLR* transcription [74].
- **Sp1 Binding Sites:** Three GC-rich boxes that bind the transcription factor Sp1. These sites are required for basal promoter activity and cooperate with SREBP-2 to achieve maximal transcriptional activation. The interaction between Sp1 and SREBP-2 is a well-characterized paradigm of promoter synergy [25, 93].
- **Sterol-Independent Regulatory Element (SIRE):** A binding site for the transcription factor Egr1 and C/EBPβ, which mediates transcriptional activation in response to cytokines such as oncostatin M (OM). This pathway operates independently of cellular sterol levels and is crucial for the inflammatory regulation of LDLR [96].

Additional regulatory complexity is provided by the liver X receptor alpha (LXRα), which has been identified as a direct transcriptional activator of *LDLR* [82]. Furthermore, the transcription factor DJ-1 (encoded by *PARK7*) has been shown to coactivate *LDLR* transcription, linking cholesterol homeostasis to oxidative stress responses and neurodegeneration [61].

### 1.3 Enhancer Elements and GWAS Variants

Genome-wide association studies (GWAS) have identified common single-nucleotide polymorphisms (SNPs) within the *LDLR* locus that influence plasma LDL cholesterol (LDL-C) levels. A prominent example is rs6511720 (G>T), located in intron 1. This SNP is associated with lower LDL-C and reduced risk of coronary heart disease (CHD). Functional studies have demonstrated that the T allele creates a binding site for the transcription factor E2F, which acts as a repressor of *LDLR* transcription, paradoxically leading to higher expression in certain contexts due to allele-specific enhancer-promoter interactions [24]. This finding highlights the complexity of non-coding regulatory variation in the *LDLR* locus.

### 1.4 Alternative Splicing and Isoforms

While *LDLR* is primarily expressed as a single major transcript, alternative splicing events have been documented. The most common splice variants involve exon 1 and the 5' UTR, which do not alter the protein sequence. However, intronic mutations can disrupt pre-mRNA splicing, leading to exon skipping, cryptic splice site activation, or intron retention. These splicing defects are a significant cause of FH, and bioinformatic tools are often used to predict their pathogenicity [56]. For instance, mutations in the invariant GT and AG dinucleotides of splice donor and acceptor sites frequently result in frameshifts and premature termination codons, leading to nonsense-mediated decay of the mutant mRNA.

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The mature LDLR protein is a type I transmembrane glycoprotein of 839 amino acids (after cleavage of the 21-amino-acid signal peptide). It is organized into five distinct functional domains, each with a specific structural fold and biological role. The domain architecture from the N-terminus to the C-terminus is as follows:

1.  **Ligand-Binding Domain (Residues 1–292):** Composed of seven tandemly repeated complement-type (class A) domains, each approximately 40 amino acids in length. Each repeat contains six conserved cysteine residues that form three disulfide bonds, creating a compact, negatively charged surface. A conserved cluster of acidic residues (Ser-Asp-Glu) within each repeat coordinates a calcium ion, which is essential for the structural integrity and ligand-binding capacity of the domain. These repeats are responsible for binding ApoB-100 and ApoE.
2.  **EGF Precursor Homology Domain (Residues 293–692):** This large domain is subdivided into three EGF-like repeats (EGF-A, EGF-B, and EGF-C) and a β-propeller domain. The EGF-like repeats are characterized by six conserved cysteines forming three disulfide bonds. The β-propeller domain is a six-bladed structure composed of ~50-amino-acid repeats, each containing a conserved YWTD motif. This domain is critical for the pH-dependent release of ligands in the endosome.
3.  **O-Linked Sugar Domain (Residues 693–767):** A serine/threonine-rich region that is heavily modified by O-glycosylation. The function of this domain is not entirely clear, but it is thought to act as a rigid stalk that extends the ligand-binding domain above the plasma membrane. Site-specific O-glycosylation of this domain has been shown to enhance ligand interactions [44].
4.  **Transmembrane Domain (Residues 768–788):** A single hydrophobic α-helix that anchors the receptor to the plasma membrane.
5.  **Cytoplasmic Tail (Residues 789–839):** The C-terminal intracellular domain contains the internalization signal, Asn-Pro-Val-Tyr (NPVY), which is essential for clustering into clathrin-coated pits. This motif interacts with the clathrin adaptor protein complex AP-2.

### 2.2 Quaternary Structure and Ligand Binding

The LDLR functions as a monomer on the cell surface. The binding of LDL is mediated by a high-affinity interaction between the ligand-binding domain and ApoB-100. A recent cryo-electron microscopy (cryo-EM) structure of the ApoB-100-LDLR complex has provided unprecedented detail into this interaction, revealing that the N-terminal portion of ApoB-100 wraps around the ligand-binding repeats, with multiple contact points [16]. The receptor also binds ApoE-containing lipoproteins, such as VLDL remnants and chylomicron remnants, with even higher affinity.

### 2.3 pH-Dependent Conformational Change

A hallmark of LDLR function is its ability to release ligands in the acidic environment of the endosome. At the neutral pH of the cell surface, the β-propeller domain is positioned away from the ligand-binding domain, allowing ligand binding. Upon endocytosis, the endosomal pH drops to ~5.5. This acidic environment protonates histidine residues in the ligand-binding domain, weakening its interaction with the ligand. Concurrently, the β-propeller domain undergoes a conformational change, folding back to interact with the ligand-binding domain. This intramolecular interaction displaces the ligand, allowing the empty receptor to recycle back to the cell surface. This pH-dependent switch is a classic example of allosteric regulation in a membrane receptor.

### 2.4 Interactive 3D Visualizer

To explore the three-dimensional structure of the LDLR protein, including its domain organization and key binding sites, please use the interactive visualizer below:

[Interactive 3D Protein Visualizer: Load LDLR (PDB: 1N7D)](/tools/protein-structure-viewer?source=direct&pdbId=1N7D)

The representative structure (PDB: 1N7D) corresponds to the extracellular domain of the human LDLR at acidic pH, capturing the receptor in its "closed" conformation with the β-propeller domain engaged with the ligand-binding domain.

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The LDLR Endocytic Pathway

The primary function of LDLR is to mediate the clearance of plasma LDL-C. The lifecycle of the receptor is a tightly regulated cycle of synthesis, trafficking, ligand binding, endocytosis, and recycling.

1.  **Synthesis and Maturation:** LDLR is synthesized in the rough endoplasmic reticulum (ER) as a precursor protein. It undergoes N-linked glycosylation and proper disulfide bond formation, which is facilitated by chaperones. The correctly folded receptor is then transported to the Golgi apparatus, where its O-linked sugar domain is glycosylated, and the N-linked glycans are processed to their mature form. Only the mature, fully glycosylated receptor is transported to the plasma membrane.
2.  **Cell Surface Expression and Ligand Binding:** At the plasma membrane, LDLR is diffusely distributed but can rapidly cluster into clathrin-coated pits. The cytoplasmic NPVY motif is recognized by the μ2 subunit of the AP-2 adaptor complex, which links the receptor to clathrin. Upon binding of LDL, the receptor-ligand complex is internalized.
3.  **Clathrin-Mediated Endocytosis:** The invagination of the coated pit is pinched off to form a clathrin-coated vesicle, a process requiring the GTPase dynamin. The vesicle is then uncoated and fuses with early endosomes.
4.  **Ligand Release and Receptor Recycling:** In the acidic endosome, the conformational change described in Section 2.3 releases the LDL particle. The free receptor is sorted into tubular extensions of the endosome and recycled back to the plasma membrane. The LDL particle is delivered to lysosomes, where ApoB-100 is degraded to amino acids and cholesteryl esters are hydrolyzed to free cholesterol.
5.  **Intracellular Cholesterol Homeostasis:** The free cholesterol released from LDL exerts profound regulatory effects on cellular cholesterol metabolism. It (a) inhibits the proteolytic activation of SREBP-2, thereby reducing the transcription of *LDLR* and HMG-CoA reductase (the rate-limiting enzyme in cholesterol synthesis); (b) activates acyl-CoA:cholesterol acyltransferase (ACAT), which esterifies excess cholesterol for storage; and (c) suppresses the transcription of the *PCSK9* gene. This coordinated feedback loop ensures that cellular cholesterol levels are maintained within a narrow physiological range.

### 3.2 Regulation by PCSK9

PCSK9 is a secreted protease that is a major post-translational regulator of LDLR. Unlike typical proteases, PCSK9's effect on LDLR does not require its catalytic activity. Instead, PCSK9 binds to the EGF-A domain of the LDLR at the cell surface. The PCSK9-LDLR complex is then internalized via clathrin-mediated endocytosis. In the acidic endosome, the binding affinity between PCSK9 and LDLR is dramatically increased, preventing the pH-dependent conformational change that normally releases the ligand. Consequently, the LDLR is unable to recycle and is sorted to the lysosome for degradation [6, 63]. By reducing the number of cell surface LDLRs, PCSK9 decreases the hepatic clearance of LDL-C, leading to higher plasma cholesterol levels. This mechanism is the basis for the development of PCSK9 inhibitors (monoclonal antibodies and small interfering RNAs) as potent cholesterol-lowering therapies.

### 3.3 The IDOL Pathway

An independent post-translational regulatory pathway involves the E3 ubiquitin ligase IDOL (Inducible Degrader of the LDLR). IDOL is transcriptionally activated by the liver X receptor (LXR) in response to high cellular oxysterol levels. IDOL ubiquitinates the cytoplasmic tail of LDLR, targeting it for degradation via the endolysosomal pathway. This pathway is particularly important in sterol-rich cells, providing a mechanism to limit further cholesterol uptake [74].

### 3.4 Signaling Beyond Endocytosis

While LDLR is primarily an endocytic receptor, emerging evidence suggests it can participate in intracellular signaling cascades. LDLR has been shown to regulate the NLRP3 inflammasome, a key component of the innate immune response. In a model of cerebral ischemia/reperfusion injury, LDLR deficiency exacerbated NLRP3-mediated neuronal pyroptosis, suggesting a protective role for LDLR in neuroinflammation [21]. Furthermore, LDLR expression influences the response to growth factors and cytokines, potentially through its role in modulating membrane cholesterol content and lipid raft organization [57].

### 3.5 Protein-Protein Interaction Networks

The LDLR interacts with a wide array of proteins beyond its primary ligands. Key interactions include:

- **ApoB-100 and ApoE:** The primary ligands for receptor-mediated endocytosis [16].
- **PCSK9:** The negative regulator that targets LDLR for lysosomal degradation [63].
- **AP-2 Adaptor Complex:** Mediates clathrin-coated pit localization via the NPVY motif.
- **ARH (Autosomal Recessive Hypercholesterolemia) Protein:** An adaptor protein required for LDLR internalization in the liver. Mutations in ARH cause a recessive form of FH.
- **CD81:** A tetraspanin that complexes with LDLR and is also targeted for degradation by PCSK9 [55].
- **LRP1:** A member of the LDLR family that shares structural and functional similarities and can compensate for some LDLR functions [30].

```mermaid
sequenceDiagram
    participant S as "Cell Surface"
    participant CP as "Clathrin-Coated Pit"
    participant E as "Early Endosome"
    participant L as "Lysosome"
    participant R as "Recycling Endosome"
    participant P as "PCSK9"
    S->>S: LDLR expressed on membrane
    S->>CP: LDLR clusters with LDL
    CP->>E: Endocytosis (clathrin-mediated)
    E->>E: pH drops (5.5)
    E->>L: LDL released & degraded
    E->>R: LDLR recycled to surface
    R->>S: LDLR re-inserted into membrane
    P->>S: PCSK9 binds LDLR
    P->>E: PCSK9-LDLR complex internalized
    E->>L: Complex sorted to lysosome (no recycling)
    L->>L: LDLR degraded
```

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Familial Hypercholesterolemia (FH)

Mutations in the *LDLR* gene are the most common cause of familial hypercholesterolemia (FH), an autosomal dominant disorder characterized by markedly elevated plasma LDL-C levels, tendon xanthomas, and premature atherosclerotic cardiovascular disease (ASCVD). Over 3,000 unique variants have been identified in the *LDLR* gene, and these are cataloged in dedicated databases [8, 23, 59]. The clinical severity of FH is highly dependent on the type of mutation, with null alleles (which produce no functional protein) resulting in a more severe phenotype than defective alleles (which produce a protein with reduced function) [49, 62].

### 4.2 Classes of LDLR Mutations

Mutations in *LDLR* are traditionally classified into five functional classes based on their molecular defect:

- **Class 1 (Null Alleles):** These mutations prevent the synthesis of any detectable protein. They include large deletions, nonsense mutations, and frameshift mutations that lead to premature termination codons and nonsense-mediated decay of the mRNA. An example is the novel nonsense variant c.1332dup, p.(D445*) identified in severely affected FH patients [42].
- **Class 2 (Transport-Defective Alleles):** These mutations produce a precursor protein that is unable to fold correctly and is retained in the ER, failing to reach the Golgi apparatus. This is the most common class of mutation. Missense mutations in the ligand-binding domain or EGF precursor domain often result in this phenotype.
- **Class 3 (Binding-Defective Alleles):** These mutations produce a receptor that reaches the cell surface but is unable to bind LDL normally. These mutations are typically located in the ligand-binding domain. The C163Y mutation, common in the west of Scotland, is a classic example of a binding-defective mutation [2].
- **Class 4 (Internalization-Defective Alleles):** These mutations produce a receptor that binds LDL but fails to cluster in clathrin-coated pits, preventing internalization. These mutations are almost exclusively located in the cytoplasmic tail, disrupting the NPVY internalization signal.
- **Class 5 (Recycling-Defective Alleles):** These mutations produce a receptor that binds and internalizes LDL but fails to release the ligand in the endosome. This is due to mutations in the EGF precursor homology domain, particularly the β-propeller, which prevents the pH-dependent conformational change. Several mutations in the EGF precursor domain have been identified in Northern Irish FH patients [3].

### 4.3 Geographic and Ethnic Variation

The spectrum of *LDLR* mutations varies significantly across different populations due to founder effects and genetic drift. For example, a few specific mutations account for the majority of FH cases in the South African Afrikaner population [81], while a broader spectrum of mutations is observed in other populations [9, 10, 47, 58]. The FH×Tonami variant is a notable founder mutation in Japan [94]. This geographic diversity underscores the importance of population-specific genetic screening strategies.

### 4.4 Genotype-Phenotype Correlations

The type of *LDLR* mutation has a direct impact on the clinical phenotype and response to therapy. Patients with receptor-negative mutations (Class 1) generally have higher baseline LDL-C levels and a higher risk of cardiovascular events compared to those with receptor-defective mutations (Classes 2–5) [33, 49, 62]. Furthermore, the response to statin therapy is influenced by the mutation type. A study on simvastatin showed that patients with certain mutations, such as the common V408M mutation, had a poorer lipid-lowering response compared to those with other mutations [83]. This variability is also observed with newer therapies, such as PCSK9 inhibitors. For example, homozygous FH patients with identical mutations can variably express the LDLR, leading to differential responses to evolocumab [31].

### 4.5 Compound Heterozygosity and Homozygosity

While FH is typically an autosomal dominant disorder, the severity is gene-dosage dependent. Homozygous FH (HoFH) and compound heterozygous FH are much more severe, with LDL-C levels often exceeding 13 mmol/L (>500 mg/dL) and presenting with extensive xanthomas and ASCVD in childhood [5, 7]. The identification of compound heterozygosity can be challenging, as demonstrated in a 76-year-old patient whose diagnosis was only confirmed through haplotype analysis [4]. The management of HoFH is complex and often requires a combination of lipid apheresis, statins, ezetimibe, and newer agents like lomitapide and PCSK9 inhibitors [5, 7].

### 4.6 Copy Number Variations

In addition to point mutations, large deletions and duplications of one or more exons of the *LDLR* gene are a significant cause of FH. These copy number variations (CNVs) are not detected by standard Sanger sequencing and require specialized techniques such as multiplex ligation-dependent probe amplification (MLPA) [53] or next-generation sequencing (NGS) with CNV analysis algorithms [38].

## 5. Host-Pathogen & Viral Interactions

Beyond its role in lipid metabolism, LDLR has been identified as a critical entry factor for a diverse range of pathogens, highlighting its importance in infectious disease.

### 5.1 Viral Entry Receptors

- **Hepatitis C Virus (HCV):** LDLR has long been implicated in HCV entry, as the virus associates with LDL and VLDL in the bloodstream. Studies using LDLR-deficient hepatocytes derived from induced pluripotent stem cells (iPSCs) have confirmed that LDLR is a productive entry factor for HCV [41].
- **Crimean-Congo Hemorrhagic Fever Virus (CCHFV):** Recent landmark studies have identified LDLR as a critical receptor for CCHFV, the most widespread tick-borne zoonotic bunyavirus. The virus uses LDLR to bind and enter host cells, and LDLR knockout cells are resistant to infection [19, 52].
- **Alphaviruses:** LDLR has been shown to promote infection of multiple encephalitic alphaviruses, including [Venezuelan equine encephalitis virus](/knowledge/viruses/livestock-viruses/venezuelan-equine-encephalitis-virus) (VEEV) and others. LDLR and its family members (VLDLR, ApoER2) serve as entry receptors, explaining the broad host range and tissue tropism of these viruses [14, 22].
- **Hepatitis B Virus (HBV):** LDLR plays an important role in HBV infection, potentially mediating the entry of HBV particles that are associated with lipoproteins [54].
- **Japanese Encephalitis Virus (JEV):** LDLR is a host factor required for JEV entry. The compound berbamine inhibits JEV infection by compromising the endolysosomal trafficking of LDLR [20].
- **Minor Group Rhinoviruses:** While the primary receptor for minor group rhinoviruses is the very low-density lipoprotein receptor (VLDLR), a member of the LDLR family, the role of LDLR itself in this process is less clear. However, the related receptor VLDLR is downregulated by miR-23b in response to viral infection, suggesting a complex regulatory network [73].

### 5.2 Bacterial Toxins

- **Clostridium difficile Toxin A (TcdA):** LDLR contributes to the entry of TcdA into colonic epithelial cells. Sulfated glycosaminoglycans and LDLR act as co-receptors for the toxin, facilitating its uptake and subsequent cytotoxicity [65].

### 5.3 Implications for Pathogenesis

The exploitation of LDLR by multiple pathogens suggests that the receptor's high endocytic capacity and broad tissue expression make it an attractive target for microbial entry. This also raises the possibility that cholesterol-lowering therapies that modulate LDLR expression could influence susceptibility to or severity of certain infections.

## 6. [Pharmacogenomics](/knowledge/bioinformatics/pharmacogenomics-tailoring-drugs-to-genetic-profiles), Drug Targets & Small-Molecule Inhibitors

LDLR is a central node in cholesterol metabolism and is the target of several classes of FDA-approved drugs. The therapeutic goal is to increase LDLR expression or activity to enhance the clearance of plasma LDL-C.

### 6.1 Statins (HMG-CoA Reductase Inhibitors)

Statins are the first-line therapy for hypercholesterolemia. By inhibiting HMG-CoA reductase, they deplete intracellular cholesterol, leading to the activation of SREBP-2. This, in turn, upregulates *LDLR* gene transcription, increasing the number of cell surface receptors and enhancing LDL-C clearance. The efficacy of statins is influenced by the specific *LDLR* mutation, as discussed in Section 4.4 [83, 90].

### 6.2 PCSK9 Inhibitors

PCSK9 inhibitors are a newer class of powerful lipid-lowering agents that act by preventing PCSK9-mediated degradation of LDLR.

- **Monoclonal Antibodies (Evolocumab, Alirocumab):** These antibodies bind to circulating PCSK9 and prevent it from interacting with LDLR. This increases the number of LDLRs available on the hepatocyte surface, leading to a dramatic reduction in plasma LDL-C levels. They are particularly effective in heterozygous FH and are also used in some homozygous FH patients with residual LDLR function [31].
- **Small Interfering RNA (Inclisiran):** This is a long-acting siRNA that targets *PCSK9* mRNA in the liver, reducing its translation. By lowering PCSK9 levels, it indirectly increases LDLR expression.

### 6.3 Other Lipid-Lowering Agents

- **Ezetimibe:** Inhibits the Niemann-Pick C1-like 1 (NPC1L1) transporter in the intestine, reducing cholesterol absorption. This leads to a compensatory increase in hepatic LDLR expression.
- **Bempedoic Acid:** An ATP-citrate lyase inhibitor that works upstream of HMG-CoA reductase. It upregulates LDLR expression through the same SREBP-2 pathway as statins. It has been shown to lower LDL-C and attenuate atherosclerosis in LDLR-deficient pig models [18].
- **Lomitapide:** A microsomal triglyceride transfer protein (MTP) inhibitor that reduces the production of VLDL in the liver. It is approved for the treatment of homozygous FH, where LDLR function is severely impaired [7].

### 6.4 Gene Therapy

Given that FH is a monogenic disorder, gene therapy has long been considered a potential cure. The goal is to deliver a functional copy of the *LDLR* gene to hepatocytes.

- **Adenoviral Vectors:** Early studies demonstrated that adenovirus-mediated delivery of the *LDLR* gene could reverse hypercholesterolemia in LDLR-deficient mice [35, 87]. However, the immunogenicity of adenoviral vectors and the transient nature of transgene expression have limited their clinical application.
- **Helper-Dependent Adenoviral Vectors:** These "gutless" vectors have reduced immunogenicity and can provide long-term transgene expression, leading to sustained reversal of hypercholesterolemia and atherosclerosis in mouse models [12, 32, 87].
- **Exosome-Based Delivery:** A novel approach using exosomes to deliver the *LDLR* gene has shown promise in a mouse model of FH, representing a potentially safer and more efficient delivery method [15].
- **Genomic Locus Delivery:** The delivery of a complete 135-kb genomic *LDLR* locus using an infectious herpesvirus-based system has been shown to lead to regulated complementation of LDLR deficiency, preserving the natural regulatory elements of the gene [66].

### 6.5 LDLR as a Target for Drug Delivery

The high expression of LDLR on hepatocytes and its natural ligand (ApoB-100 or ApoE) have been exploited for targeted drug delivery. Lipid nanoparticles (LNPs) can be engineered to adsorb ApoE, which then facilitates their uptake into hepatocytes via LDLR [34, 51]. This approach has been used to deliver chemotherapeutic agents, such as Sorafenib and Dihydroartemisinin, to liver cancers [26]. Furthermore, the LDLR pathway is being explored for the delivery of mRNA-based therapeutics [34].

### 6.6 LDLR in Cancer

The role of LDLR in cancer is complex and context-dependent. Many cancer cells have an increased demand for cholesterol to support rapid proliferation, and they often upregulate LDLR expression to meet this demand. High LDLR expression has been identified as an independent adverse prognostic factor in acute myeloid leukemia (AML), where it contributes to chemotherapy resistance [13]. In other cancers, such as breast cancer, the role of the LDLR family is more nuanced, with different members playing distinct roles in tumor progression [69]. This has led to the exploration of LDLR as a therapeutic target in oncology, either by inhibiting its function to starve cancer cells of cholesterol or by exploiting it for targeted drug delivery [37].

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions and resources for the *LDLR* gene and protein.

| **Database** | **Identifier / Link** | **Description** |
| :--- | :--- | :--- |
| **NCBI Gene** | [ID: 3949](https://www.ncbi.nlm.nih.gov/gene/3949) | Gene-specific information, including genomic context, transcripts, and expression data. |
| **Ensembl** | [ENSG00000130164](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000130164) | Comprehensive genome annotation, including splice variants, regulatory elements, and comparative genomics. |
| **UniProt** | [P01130](https://www.uniprot.org/uniprotkb/P01130/entry) | Protein sequence, function, post-translational modifications, and domain architecture. |
| **RCSB PDB** | [1N7D](https://www.rcsb.org/structure/1N7D) | Experimentally determined 3D structure of the extracellular domain. |
| **ClinVar** | [LDLR](https://www.ncbi.nlm.nih.gov/clinvar/?term=LDLR%5Bgene%5D) | Database of human genetic variants and their clinical significance. |
| **OMIM** | [606945](https://www.omim.org/entry/606945) | Catalog of human genes and genetic phenotypes. |
| **Gene Ontology (GO)** | [GO:0005041](https://www.ebi.ac.uk/QuickGO/term/GO:0005041) (low-density lipoprotein particle receptor activity), [GO:0006898](https://www.ebi.ac.uk/QuickGO/term/GO:0006898) (receptor-mediated endocytosis) | Standardized vocabulary for gene function, process, and cellular component. |
| **STRING** | [P01130](https://string-db.org/network/9606.ENSP00000252444) | Protein-protein interaction networks. |
| **BioGRID** | [LDLR](https://thebiogrid.org/112658) | Curated protein and genetic interactions. |
| **LDLR Variant Database (UCL)** | [LDLR DB](https://www.ucl.ac.uk/ldlr/LOVDv.1.1.0/) | Dedicated database for LDLR variants and their pathogenicity [23, 59]. |

## Related Clinical & Scientific Guides

* [IRF6 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/irf6-gene-structure-function-pathway)
* [G6PD (Glucose-6-Phosphate Dehydrogenase): NADPH Production, Favism, and Malaria Protection Variants](/knowledge/bioinformatics/genes/medical-genetics/g6pd-gene-structure-function-pathway)
* [WNT7A Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/wnt7a-gene-structure-function-pathway)


## References

1.  Zheng, F. (2000). The influence of traditional Chinese medicine on expression level of lowdensity lipoprotein receptor gene. *Scientific Publication*. [Link](https://www.semanticscholar.org/paper/dd1b11648d10f31873516a302e05f71bdbf9193b)
2.  Lee, W., Dorrance, A., Dominiczak, M., Packard, C., & Dominiczak, A. (1998). Identification of a common lowdensity lipoprotein receptor mutation (C163Y) in the west of Scotland. *Scientific Publication*. [Link](https://www.semanticscholar.org/paper/084e21319f6bde3a9e6cfa6b60b4227aedccb226)
3.  Ward, A., O’Kane, M., Young, I., Nicholls, D., Nevin, N., Graham, C., & Ok, M. (2005). MUTATION IN BRIEF Three Novel Receptor Gene in Northern Irish Patients With Familial Hypercholesterolemia tations in the EGF Precursor Domain of the Low-Densiw Lipoprotein. *Scientific Publication*. [Link](https://www.semanticscholar.org/paper/9b3f922f563797e608bf1d1ae9684860d62d4503)
4.  Fischer, H., Schuster, H., Keller, C., Wolfram, G., & Zöllner, N. (1991). Identification of a 76-year-old patient with compound heterozygous Familial Hypercholesterolemia by haplotype analysis of the LDL receptor gene. *Klinische Wochenschrift*. [Link](https://www.semanticscholar.org/paper/93b72838f6010814cf95f1a709bd9c38e3bcfabc)
5.  Khong, S. C., Gunasegaran, A., Hamza, N., Aziz, H., Mazlan, S., & Katiman, E. (2023). SUCCESSFUL PREGNANCY IN A HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA PATIENT REQUIRING LIPID APHERESIS AND MULTIDISCIPLINARY TEAM MANAGEMENT. *Journal of the ASEAN Federation of Endocrine Societies*. [Link](https://www.semanticscholar.org/paper/0511bd75d75706877b6b656be324a6c86570b139)
6.  Wierzbicki, A. (2007). Proprotein convertase subtilisin/kexin type 9, its variants and regulation of low-density lipoprotein cholesterol. *Current Opinion in Lipidology*. [Link](https://www.semanticscholar.org/paper/a7d02533259a8677aca0be22ed1aa49b07a18b33)
7.  Kim, S.-H., & Baek, S. (2020). Lomitapide, relief pitcher for patients with homozygous familial hypercholesterolemia. *European Journal of Preventive Cardiology*. [Link](https://www.semanticscholar.org/paper/906b5ea5cb82df3cb02f6757f9bccd8c70be2152)
8.  Heath, K., Gahan, M., Whittall, R., & Humphries, S. (2001). Low-density lipoprotein receptor gene (LDLR) world-wide website in familial hypercholesterolaemia: update, new features and mutation analysis. *Atherosclerosis*. [Link](https://www.semanticscholar.org/paper/c8d24b5444b2be5047b36e0081101670c6497a26)
9.  Miltiadous, G., Elisaf, M., Bairaktari, H., Xenophontos, S., Manoli, P., & Cariolou, M. (2001). Characterization and geographic distribution of the low density lipoprotein receptor (LDLR) gene mutations in northwestern Greece. *Human Mutation*. [Link](https://www.semanticscholar.org/paper/adadc15e2a7ae929093b1bb24763d8c46b955ded)
10. Wang, J., Huff, E., Janecka, L., & Hegele, R. (2001). Low density lipoprotein receptor (LDLR) gene mutations in Canadian subjects with familial hypercholesterolemia, but not of French descent. *Human Mutation*. [Link](https://www.semanticscholar.org/paper/7c310f61cbf3d9dbcde18b603eee4d9c5e